A Double-Blind, Single-Center, Randomized, Placebo Controlled Safety, Tolerability & Efficacy Trial Of A New Botanical Drug Product At One Dose Level For The Treatment Of Mild-To-Moderate Plaque Psoriasis In Adult Subjects
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Santalum album (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Santalis Pharmaceuticals
- 04 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 04 Oct 2017 Planned primary completion date changed from 1 Nov 2017 to 1 May 2018.
- 04 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.